8-K/A

Date: March 4, 2022

/s/ Rohan Palekar

Rohan Palekar

Chief Executive Officer

0001193125-22-066288.txt : 20220304 0001193125-22-066288.hdr.sgml : 20220304 20220304170617 ACCESSION NUMBER: 0001193125-22-066288 CONFORMED SUBMISSION TYPE: 8-K/A PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20220217 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220304 DATE AS OF CHANGE: 20220304 FILER: COMPANY DATA: COMPANY CONFORMED NAME: 89bio, Inc. CENTRAL INDEX KEY: 0001785173 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 831114349 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K/A SEC ACT: 1934 Act SEC FILE NUMBER: 001-39122 FILM NUMBER: 22715113 BUSINESS ADDRESS: STREET 1: 535 MISSION STREET STREET 2: 14TH FLOOR CITY: SAN FRANCISCO STATE: CA ZIP: 94105 BUSINESS PHONE: 4155004614 MAIL ADDRESS: STREET 1: 535 MISSION STREET STREET 2: 14TH FLOOR CITY: SAN FRANCISCO STATE: CA ZIP: 94105 8-K/A 1 d313986d8ka.htm 8-K/A 8-K/A

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K/A

(Amendment No. 1)

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 17, 2022

89bio, Inc.

(Exact name of registrant as specified in its charter)

Delaware

001-39122

36-4946844

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

142 Sansome Street, Second Floor

San Francisco, CA 94104

(Address of principal executive offices, including zip code)

(415) 500-4614

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading

Symbol(s)

Name of each exchange

on which registered

Common Stock, par value $0.001 per share

ETNB

The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Explanatory Note:

This Amendment to the Current Report on Form 8-K filed with the Securities and Exchange Commission on February 24, 2022 is being filed to correct a typographical error in the effective date of Dr. Atkinson’s appointment to the Board.

Item 5.02

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Director Appointment

On February 17, 2022, the board of directors (the “Board”) of 89bio, Inc. (the “Company”) appointed Edward Morrow Atkinson III as a member of the Board. Dr. Atkinson will serve as a Class I Director until the Company’s 2023 Annual Meeting of Stockholders and until his successor is duly elected and qualified, effective immediately.

Dr. Atkinson, age 56, has over 20 years of experience in biopharmaceutical development, launch, manufacturing and supply chain. Dr. Atkinson has served as Senior Vice President, Head of Commercial Manufacturing and Supply Chain for Vertex Pharmaceuticals, Inc., a biopharmaceutical company, since July 2020. From 2012 to June 2020, Dr. Atkinson served in various roles at Bristol Myers Squibb, a biopharmaceutical company, including as Senior Vice President of Global Manufacturing Operations from September 2019 to June 2020, Vice President and Integration Leader of Manufacturing and Cell Therapy from January 2019 to September 2019, Vice President of Internal Manufacturing, Biologics from June 2017 to January 2019 and Vice President of Biologics Development and Clinical Manufacturing from 2012 to June 2017. Prior to that, Dr. Atkinson served in roles at Cook Pharmica, LLC (now Catalent), Eli Lilly & Co., Targeted Genetics Corporation and Geron Corporation. Dr. Atkinson earned his B.S. in Biology from Indiana University-Bloomington and Ph.D. in Biological Sciences from Stanford University.

In accordance with the Company’s non-employee director compensation policy, which is described in the Company’s Proxy Statement on Schedule 14A filed with the Securities and Exchange Commission on April 15, 2021, Dr. Atkinson will receive an annual cash retainer of $40,000 for his service as a member of the Board. In addition, Dr. Atkinson was granted an option to purchase 30,000 shares of the Company’s common stock at an exercise price equal to the closing price of the Company’s common stock on The Nasdaq Global Market on the date of grant. The equity award was made under the Company’s Amended and Restated 2019 Equity Incentive Plan. The shares underlying the option will vest and become exercisable on the first, second and third anniversary of February 17, 2022, subject to Dr. Atkinson’s continued service to the Company. Dr. Atkinson has entered into the Company’s standard form of indemnification agreement, which was previously filed by the Company as Exhibit 10.1 to the Company’s Form S-1 filed on October 11, 2019.

There are no arrangements or understandings between Dr. Atkinson and any other persons pursuant to which he was elected as a director of the Company. There are no family relationships between Dr. Atkinson and any director or executive officer of the Company, and he has no direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.

On February 24, 2022, the Company issued a press release announcing Dr. Atkinson’s appointment. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

Item 9.01

Financial Statements and Exhibits

(d) Exhibits. The following exhibit is being furnished herewith:

EXHIBIT INDEX


Exhibit No.		Description

99.1		Press Release, dated February 24, 2022

104		Cover page interactive data file (embedded within the inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

EX-99.1 2 d313986dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

LOGO

89bio Announces Appointment of E. Morrey Atkinson, Ph.D., to its Board of Directors

SAN FRANCISCO, February 24, 2022 (GLOBE NEWSWIRE) — 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced the appointment of E. Morrey Atkinson, Ph.D., to its Board of Directors. Dr. Atkinson currently serves as Senior Vice President, Head of Commercial Manufacturing and Supply Chain of Vertex Pharmaceuticals.

“As a seasoned biopharmaceutical industry veteran with deep-rooted expertise, Morrey is a welcome addition to our Board of Directors,” said Rohan Palekar, Chief Executive Officer of 89bio. “Morrey brings extensive knowledge of biologic development, manufacturing, and scale-up, including direct experience with FGF-based therapies. Additionally, he has a strong track record for optimizing manufacturing and supply chain capabilities, as well as advancing and commercializing high-quality, differentiated drug candidates for patients. His strategic insights and broad operational experience will be invaluable as we execute on our ongoing clinical development program for pegozafermin.”

Dr. Atkinson added, “I am delighted to join the Board of Directors of 89bio, especially in light of the company’s recent positive data from the Phase 1b/2a study of pegozafermin. I am incredibly excited about pegozafermin’s compelling differentiated profile in NASH and SHTG, and I look forward to working towards real change for patients alongside 89bio’s exceptional team.”

Dr. Atkinson brings over 20 years of experience in biopharmaceutical development, launch, manufacturing and supply chain. Prior to his role at Vertex, Dr. Atkinson served in a number of roles at Bristol Myers Squibb, including most recently as Senior Vice President of Global Manufacturing Operations, where he helped lead the manufacturing and cell therapy integration team for Bristol Myers Squibb’s $74 billion merger with Celgene. Prior to Bristol Myers Squibb, he served as Chief Scientific Officer at Cook Pharmica (now Catalent) and Head of Biologics Development & Manufacturing Sciences at Eli Lilly, where he specialized in biologics, manufacturing and development. Throughout his career, he has participated in the development, commercialization and manufacturing of multiple commercial products, including FORTEO^®, TRULICITY^®, TALTZ^®, TRIKAFTA^®, OPDIVO^®, EMPLICITI^®, YERVOY^®, ELIQUIS^® AND ORENICA^®. He has also been instrumental in spearheading the building and qualification of R&D and commercial manufacturing facilities across the United States and Europe. Dr. Atkinson holds a Ph.D. from Stanford University in Biological Sciences and a B.S. from Indiana University in Biology.

About 89bio

89bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases. The company’s lead product candidate, pegozafermin, is a specifically engineered glycoPEGylated analog of FGF21. Pegozafermin is being developed for the treatment of nonalcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG). 89bio is headquartered in San Francisco with operations in Herzliya, Israel. For more information, visit www.89bio.com or follow the company on LinkedIn.

Investor Contact:

Ryan Martins

Chief Financial Officer

investors@89bio.com

EX-101.SCH 3 etnb-20220217.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 4 etnb-20220217_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company Entity Ex Transition Period Entity Ex Transition Period Amendment Description Amendment Description EX-101.PRE 5 etnb-20220217_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 g313986g02d35.jpg GRAPHIC begin 644 g313986g02d35.jpg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end XML 7 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information	Feb. 17, 2022
Cover [Abstract]
Amendment Flag	true
Entity Central Index Key	0001785173
Document Type	8-K/A
Document Period End Date	Feb. 17, 2022
Entity Registrant Name	89bio, Inc.
Entity Incorporation State Country Code	DE
Entity File Number	001-39122
Entity Tax Identification Number	36-4946844
Entity Address, Address Line One	142 Sansome Street
Entity Address, Address Line Two	Second Floor
Entity Address, City or Town	San Francisco
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	94104
City Area Code	(415)
Local Phone Number	500-4614
Written Communications	false
Soliciting Material	false
Pre Commencement Tender Offer	false
Pre Commencement Issuer Tender Offer	false
Security 12b Title	Common Stock, par value $0.001 per share
Trading Symbol	ETNB
Security Exchange Name	NASDAQ
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Amendment Description	This Amendment to the Current Report on Form 8-K filed with the Securities and Exchange Commission on February 24, 2022 is being filed to correct a typographical error in the effective date of Dr. Atkinson’s appointment to the Board.

XML 8 d313986d8ka_htm.xml IDEA: XBRL DOCUMENT 0001785173 2022-02-17 2022-02-17 true 0001785173 8-K/A 2022-02-17 89bio, Inc. DE 001-39122 36-4946844 142 Sansome Street Second Floor San Francisco CA 94104 (415) 500-4614 false false false false Common Stock, par value $0.001 per share ETNB NASDAQ true false This Amendment to the Current Report on Form 8-K filed with the Securities and Exchange Commission on February 24, 2022 is being filed to correct a typographical error in the effective date of Dr. Atkinson’s appointment to the Board. EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.0.1 html 1 118 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.89bio.com//20220217/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d313986d8ka.htm d313986dex991.htm etnb-20220217.xsd etnb-20220217_lab.xml etnb-20220217_pre.xml http://xbrl.sec.gov/dei/2021 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d313986d8ka.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "d313986d8ka.htm" ] }, "labelLink": { "local": [ "etnb-20220217_lab.xml" ] }, "presentationLink": { "local": [ "etnb-20220217_pre.xml" ] }, "schema": { "local": [ "etnb-20220217.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "https://xbrl.sec.gov/naics/2021/naics-2021.xsd" ] } }, "elementCount": 26, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 118, "memberCustom": 0, "memberStandard": 0, "nsprefix": "etnb", "nsuri": "http://www.89bio.com/20220217", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "d313986d8ka.htm", "contextRef": "duration_2022-02-17_to_2022-02-17", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.89bio.com//20220217/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "d313986d8ka.htm", "contextRef": "duration_2022-02-17_to_2022-02-17", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description", "terseLabel": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.89bio.com//20220217/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.89bio.com//20220217/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.89bio.com//20220217/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.89bio.com//20220217/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.89bio.com//20220217/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.89bio.com//20220217/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.89bio.com//20220217/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.89bio.com//20220217/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.89bio.com//20220217/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.89bio.com//20220217/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.89bio.com//20220217/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.89bio.com//20220217/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.89bio.com//20220217/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.89bio.com//20220217/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.89bio.com//20220217/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.89bio.com//20220217/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.89bio.com//20220217/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.89bio.com//20220217/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.89bio.com//20220217/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.89bio.com//20220217/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.89bio.com//20220217/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.89bio.com//20220217/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.89bio.com//20220217/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.89bio.com//20220217/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.89bio.com//20220217/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r7": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" } }, "version": "2.1" } ZIP 15 0001193125-22-066288-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-22-066288-xbrl.zip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end